-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Initiates Coverage On Immunic with Buy Rating, Announces Price Target of $2.5

Benzinga·04/17/2026 11:07:53
Listen to the news
Stifel analyst Paul Matteis initiates coverage on Immunic (NASDAQ:IMUX) with a Buy rating and announces Price Target of $2.5.